Arsenic-induced APL differentiation in cerebrospinal fluid

Leukemia Research

Volumn 31, Issue 5, 2007, Pages 703-705

  Helwig, Annett ^a   Klemm, Matthias ^b   Schüttig, Reinhard ^b   Röllig, Christoph ^a   Wassilew, Nasstasja ^a   Ehninger, Gerhard ^a   Illmer, Thomas ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

Author keywords

APL; Arsenic trioxide; Cerebrospinal fluid; Treatment

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; IDARUBICIN; MITOXANTRONE; RETINOIC ACID;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLEEDING; BLOOD BRAIN BARRIER; CANCER RADIOTHERAPY; CASE REPORT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CYTOPENIA; DIPLOPIA; DRUG BLOOD LEVEL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; HEADACHE; HUMAN; LEUKEMIA RELAPSE; NERVE COMPRESSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC AGENTS; ARSENICALS; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CEREBROSPINAL FLUID; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTES; OXIDES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 34147101020     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.06.011     Document Type: Article

References (6)

1. Tallman M.S., Andersen J.W., Schiffer C.A., et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100 13 (2002) 4298-4302
2. de Botton S., Sanz M.A., Chevret S., et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 20 1 (2006) 35-41
3. Diverio D., Rossi V., Awisati G., et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial1-8. Blood 92 3 (1998) 784-789
4. Au W.Y., Tam S., Fong B.M., et al. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia. Blood 107 7 (2006) 3012-3013
5. Douer D., and Tallman M.S. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23 10 (2005) 2396-2410
6. 3 exerts dose-dependent dual effects on APL cells. Blood 89 9 (1997) 3345-3353